Two-year outcome of a combination of weight loss therapies for type 2 diabetes.
OBJECTIVE
To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes.


METHODS
A total of 59 overweight or obese individuals with type 2 diabetes were randomly assigned to either a combination therapy weight loss program for 2 years (C therapy) or a standard therapy weight loss program for 1 year followed by a combination therapy weight loss program in the 2nd year (S/C therapy). C therapy combined the use of meal replacement products, repetitive intermittent low-calorie-diet weeks, and pharmacologic therapy with sibutramine. Outcome measures included changes in weight, glycemic control, plasma lipids, blood pressure, and body composition over 2 years.


RESULTS
A total of 48 participants (23 in the C therapy group and 25 in the S/C therapy group) completed 2 years of study. After 2 years, the C therapy group had weight loss of 4.6 +/- 1.2 kg (P < 0.001) and a decrease in HbA(1c) of 0.5 +/- 0.3% (P = 0.08) from baseline. At 2 years, the C therapy group had significant reductions in BMI, fat mass, lean body mass, and systolic blood pressure. The S/C therapy group showed changes in weight and HbA(1c) in year 2 of the study that were similar to those demonstrated by the C therapy group in year 1.


CONCLUSIONS
This combination weight loss program resulted in significant weight loss and improved diabetes control over a 2-year period in overweight subjects with type 2 diabetes.
Redmon
J Bruce
JB
Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota, MMC 101, 420 Delaware St. SE, Minneapolis, MN 55455, USA. redmo001@umn.edu
Reck
Kristell P
KP
Raatz
Susan K
SK
Swanson
Joyce E
JE
Kwong
Christine A
CA
Ji
Hong
H
Thomas
William
W
Bantle
John P
JP
D001067:Appetite Depressants; D015992:Body Mass Index; D001835:Body Weight; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000627:therapeutic use; D048909:Diabetes Complications / Q000534:rehabilitation*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology / Q000628:therapy*; D004038:Diet, Reducing; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000534:rehabilitation*; D016896:Treatment Outcome; D015431:Weight Loss
D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine